Trials / Withdrawn
WithdrawnNCT05882305
KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Kousai Bio Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the tolerability and feasibility of KSD-101 in patients with EBV-associated haematologic neoplasms,to observe the characteristics of dose-limiting toxicity (DLT)and to explore the range of effective dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous monocyte-derived DCs pulsed withEBV-associated antigen | Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times. |
Timeline
- Start date
- 2023-06-10
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
- First posted
- 2023-05-31
- Last updated
- 2024-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05882305. Inclusion in this directory is not an endorsement.